Skip to main content
SpringerLink
Log in

Intravitreale Injektion

Kontrollen zur Vermeidung von postoperativen Komplikationen

Intravitreal injection

Monitoring to avoid postoperative complications

  • Leitthema
  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

Zusammenfassung

Die intravitreale Injektion gilt allgemein als sicher. Viele mögliche Komplikationen durch die Prozedur sind extrem selten und können bei gewissenhafter Inspektion vor der Injektion und sachgerechter Durchführung vermieden werden. Daneben können in seltenen Fällen aber auch die applizierten Medikamente unterschiedliche pharmakologische Nebenwirkungen hervorrufen. In dieser Übersicht werden die Sicherheitsprofile von Macugen® und Lucentis® aus den Zulassungsstudien zusammengefasst sowie erste Erkenntnisse über mögliche oder beobachtete Nebenwirkungen nach intravitrealer Gabe von Avastin® beschrieben. Daneben werden wichtige Hinweise zur Vermeidung von intra- und postoperativen Komplikationen gegeben.

Abstract

Intravitreal injection is generally regarded as safe. Many of the potential complications caused by this procedure are extremely rare and can be avoided by careful inspection beforehand and proper performance of the injection. In rare cases, however, the administered drugs may cause various pharmacological side effects. This article summarizes the safety profiles of Macugen® and Lucentis® from the drug approval studies and describes initial findings on possible or observed side effects after intravitreal administration of Avastin®. In addition, important points to observe in order to avoid intra- and postoperative complications are provided.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6

Notes

  1. Persönliche Mitteilungen PD Wegener, Bonn.

  2. Maia et al. ARVO 2007.

  3. Persönliche Mitteilungen Professor Schilling.

  4. Tezel et al. (2006) 24th annual ASRS meeting, 6th annual EVRS meeting, Cannes, France 2006.

  5. Persönliche Mitteilungen Dr. Krohne, Bonn.

Literatur

  1. Ach T, Dawczynski J, Konigsdorffer E et al. (2007) Subjective sensations after intravitreal injection of bevacizumab. Klin Monatsbl Augenheilkd 224: 180–184

    Article  PubMed  CAS  Google Scholar 

  2. Aggio FB, Farah ME, de Melo GB et al (2007) Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection. Eye 21: 408–409

    Article  PubMed  CAS  Google Scholar 

  3. Aiello LP, Brucker AJ, Chan S et al (2004) Evolving guidelines for intravitreous injections. Retina 24: S3–19

    Article  PubMed  Google Scholar 

  4. Aisenbrey S, Ziemssen F, Völker M et al. (2007) Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 245: 941–948

    Article  PubMed  CAS  Google Scholar 

  5. Avery RL, Pearlman J, Pieramici DJ et al (2006) Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113: 1695.e1–15

    Article  PubMed  Google Scholar 

  6. Bakri SJ, Snyder MR, Reid JM et al (2007) Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114: 855–859

    Article  PubMed  Google Scholar 

  7. Beer PM, Wong SJ, Hammad AM et al (2006) Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 26: 871–876

    Article  PubMed  Google Scholar 

  8. Benz MS, Albini TA, Holz ER et al. (2006) Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide. Ophthalmology 113: 1174–1178

    Article  PubMed  Google Scholar 

  9. Binder CA, Mino de Kaspar H, Klauss V, Kampik A (1999) Preoperative infection prophylaxis with 1% povidon-iodine solution based on the example of conjunctival staphylococci. Ophthalmologe 96: 663–667

    Article  PubMed  CAS  Google Scholar 

  10. Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355: 1432–1444

    Article  PubMed  CAS  Google Scholar 

  11. Boyer DS, Antoszyk AN, Awh CC et al. (2007) Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114: 246–252

    Article  PubMed  Google Scholar 

  12. Chan CK, Meyer CH, Gross JG et al (2007) Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 27: 541–551

    Article  PubMed  Google Scholar 

  13. Charles S, Rosenfeld PJ, Gayer S (2007) Medical consequences of stopping anticoagulant therapy before intraocular surgery or intravitreal injections. Retina 27: 813–815

    Article  PubMed  Google Scholar 

  14. Chen SD, Mohammed Q, Bowling B et al (2004) Vitreous wick syndrome – a potential cause of endophthalmitis after intravitreal injection of triamcinolone through the pars plana. Am J Ophthalmol 137: 1159–1160

    Article  PubMed  Google Scholar 

  15. Chong NV, Adewoyin T (2007) Intravitreal injection: balancing the risks. Eye 21: 313–316

    Article  PubMed  CAS  Google Scholar 

  16. Dayani PN, Siddiqi OK, Holekamp NM (2007) Safety of intravitreal injections in patients receiving warfarin anticoagulation. Am J Ophthalmol 14: 451–453

    Article  CAS  Google Scholar 

  17. Degenring RF, Jonas JB (2004) Serum levels of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol 137: 1142–1143

    Article  PubMed  CAS  Google Scholar 

  18. Deutsche Ophthalmologische Gesellschaft, Retinologische Gesellschaft, Berufsverband der Augenärzte (2007) Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft, des Berufsverbandes der Augenärzte Deutschlands zu aktuellen therapeutischen Möglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration. Klin Monatsbl Augenheilkd 224: 559–566

    Article  Google Scholar 

  19. Dwinger MC, Pieper-Bodeewes I, Eter N, Holz FG (2005) Augeninnendruck und Notwendigkeit einer Parazentese unmittelbar nach intravitrealer Triamcinolon-Injektion. Klin Monatsbl Augenheilkd 222: 638–642

    Article  PubMed  CAS  Google Scholar 

  20. Frenkel RE, Mani L, Toler AR, Frenkel MP (2007) Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma. Am J Ophthalmol 143: 1034–1035

    Article  PubMed  CAS  Google Scholar 

  21. Fung AE, Rosenfeld PJ, Reichel E (2006) The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90: 1344–1349

    Article  PubMed  CAS  Google Scholar 

  22. Gaudreault J, Fei D, Rusit J et al. (2005) Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 46: 726–733

    Article  PubMed  Google Scholar 

  23. Gragoudas ES, Adamis AP, Cunningham ET et al. (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805–2816

    Article  PubMed  CAS  Google Scholar 

  24. Gillies MC (2006) What we don’t know about avastin might hurt us. Arch Ophthalmol 124: 1478–1479

    Article  PubMed  Google Scholar 

  25. Gupta R, Negi A, Vernon SA (2005) Severe subconjunctival hemorrhage following intravitreal triamcinolone for refractory diabetic oedema. Eye 19: 590–591

    Article  PubMed  CAS  Google Scholar 

  26. Hariprasad SM, Shah GK, Blinder KJ (2006) Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection. Am J Ophthalmol 141: 200–201

    Article  PubMed  CAS  Google Scholar 

  27. Heiduschka P, Fietz H, Hofmeister S, Tübingen Bevacizumab Study Group (2007) Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 48: 2814–2823

    Article  PubMed  Google Scholar 

  28. Heimann H (2007) Intravitreal injections: Techniques and sequelae. In: Holz FG, Spaide RF (eds) Essentials in ophthalmology-medical retina. Springer, Berlin Heidelberg New York Tokyo, pp 67–89

  29. Helbig H, Noske W, Kleineidam M et al. (1995) Bacterial endophthalmitis after anterior chamber paracentesis. Br J Ophthalmol 79: 866

    Article  PubMed  CAS  Google Scholar 

  30. Iriyama A, Chen YN, Tamaki Y, Yanagi Y (2007) Effect of the anti-VEGF antibody on the retinal ganglion cells of rat. Br J Ophthalmol 91: 1230–1233

    Article  PubMed  Google Scholar 

  31. Jaissle GB, Szurman P, Bartz-Schmidt KU et al. (2005) Recommendation for the implementation of intravitreal injections – statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (visual acuity). Klin Monatsbl Augenheilkd 222: 390–395

    Article  PubMed  CAS  Google Scholar 

  32. Jaissle GB, Szurman P, Bartz-Schmidt KU (2004) Nebenwirkungen und Komplikationen der intravitrealen Triamcinolon-acetonid-Therapie. Ophthalmologe 101: 121–128

    Article  PubMed  CAS  Google Scholar 

  33. Jonas JB, Kreissig I, Degenring RF (2004) Retinal complications of intravitreal injections of triamcinolone acetonide. Graefes Arch Clin Exp Ophthalmol 242: 184–185

    Article  PubMed  Google Scholar 

  34. Jonas JB, Degenring RF, Kreissig I et al. (2005) Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 112: 593–598

    Article  PubMed  Google Scholar 

  35. Jonas JB, Spandau UH, Rensch F et al. (2007) Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther 23: 240–242

    Article  PubMed  CAS  Google Scholar 

  36. Kernt M, Neubauer AS, Kampik A (2007) Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure. Acta Ophthalmol Scand 85: 119–120

    Article  PubMed  CAS  Google Scholar 

  37. Kernt M, Welge-Lüßen U, Yu A et al. (2007) Bevacizumab wirkt nicht toxisch auf Zellen des menschlichen Auges. Ophthalmologe 104: 965–971

    Article  PubMed  CAS  Google Scholar 

  38. Kiss C, Michels S, Prager F et al (2006) Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. Retina 26: 877–881

    Article  PubMed  Google Scholar 

  39. Kook D, Wolf A, Neubauer AS et al (2007) Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD: fequency and progress. Ophthalmologe (Jul 25 online; in diesem Heft)

  40. Kotliar K, Maier M, Bauer S et al. (2007) Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol Scand 85: 777–781

    Article  PubMed  Google Scholar 

  41. Kreissig I, Degenring RF, Jonas JB (2006) Intravitreales Triamcinolon acetonid Komplikation von infektiöser und steriler Endophthalmitis. Ophthalmologe 103: 30–34

    Article  PubMed  CAS  Google Scholar 

  42. Ladewig MS, Ziemssen F, Jaissle G et al. (2006) Intravitreales Bevacizumab bei der neovaskulären altersabhängigen Makuladegeneration. Ophthalmologe 103: 463–470

    Article  PubMed  CAS  Google Scholar 

  43. Lee EW, Hariprasad SM, Mieler WF et al. (2007) Short-term intraocular pressure trends after intravitreal triamcinolone injection. Am J Ophthalmol 143: 365–367

    Article  PubMed  CAS  Google Scholar 

  44. Ley EJ, Vukasin P, Kaiser AM et al. (2007) Delayed rectovaginal fistula: a potential complication of bevacizumab (avastin). Dis Colon Rectum 50: 930

    Article  PubMed  Google Scholar 

  45. Lin JM, Tsai YY, Chiu YT, Hung PT (2006) Paracentesis before or after intravitreal injection of triamcinolone acetonide and its necessity? Am J Ophthalmol 141: 985–986

    Article  PubMed  Google Scholar 

  46. Luke M, Warga M, Ziemssen F et al. (2006) Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol 90: 1178–1182

    Article  PubMed  CAS  Google Scholar 

  47. Manzano RP, Peyman GA, Khan P, Kivilcim M (2006) Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26: 257–261

    Article  PubMed  Google Scholar 

  48. Mennel S, Callizo J, Schmidt JC, Meyer CH (2007) Acute retinal pigment epithelial tear in the untreated fellow eye following repeated bevacizumab (Avastin) injections. Acta Ophthalmol Scand 85: 689–690

    Article  PubMed  Google Scholar 

  49. Meyer CH, Mennel S, Schmidt JC, Kroll P (2006) Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration. Br J Ophthalmol 90: 1207–1208

    Article  PubMed  CAS  Google Scholar 

  50. Meyer CH, Callizo J, Mennel S, Kussin A (2007) Perioperative management of anticoagulated patients undergoing repeated intravitreal injections. Arch Ophthalmol 125: 994

    Article  PubMed  Google Scholar 

  51. Meyer CH Eter N (2008) Incidence of of ocular hemorrhages in anticoagulated patients receiving repeated intravitreal injections. Am J Ophthalmol 145: 386–387

    Article  PubMed  Google Scholar 

  52. Meyer CH, Mennel S, Hörle S, Schmidt JC (2007) Visual hallucinations after intravitreal injection of bevacizumab in vascular age-related macular degeneration. Am J Ophthalmol 143: 169–170

    Article  PubMed  CAS  Google Scholar 

  53. Meyer CH, Mennel S, Eter N (2007) Endophthalmitisrate mit und ohne topischer postoperativer Antibiotikagabe nach intravitrealer Avastininjektion. Ophthalmologe 104: 952–957

    Article  PubMed  CAS  Google Scholar 

  54. Mordenti J, Cuthbertson RA, Ferrara N et al. (1999) Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 27: 536–544

    Article  PubMed  CAS  Google Scholar 

  55. Moshfeghi AA, Rosenfeld PJ, Puliafito CA et al. (2006) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113: 2002.e1–12

    Article  PubMed  Google Scholar 

  56. Pieramici DJ, Avery RL, Castellarin AA et al. (2006) Case of anterior uveitis after intravitreal injection of bevacizumab. Retina 26: 841–842

    Article  PubMed  Google Scholar 

  57. Rich RM, Rosenfeld PJ, Puliafito CA et al. (2006) Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26: 495–511

    Article  PubMed  Google Scholar 

  58. Rodrigues EB, Meyer CH, Schmidt JC et al. (2004) Unsealed sclerotomy after intravitreal injection with a 30-gauge needle. Retina 24: 810–812

    Article  PubMed  Google Scholar 

  59. Rodrigues EB, Meyer CH, Grumann A et al. (2007) Tunneled scleral incision to prevent vitreal reflux after intravitreal injection. Am J Ophthalmol 143: 1035–1037

    Article  PubMed  Google Scholar 

  60. Rodrigues EB, Shiroma H, Meyer CH et al. (2007) Metrorrhagia after intravitreal injection of bevacizumab. Acta Ophthalmol Scand 85: 915–916

    Article  PubMed  Google Scholar 

  61. Rosenfeld PJ, Schwartz SD, Blumenkranz MS et al. (2005) Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 112: 1048–1053

    Article  PubMed  Google Scholar 

  62. Rosenfeld PJ, Brown DM, Heier JS et al. (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419–1431

    Article  PubMed  CAS  Google Scholar 

  63. Scappaticci FA, Fehrenbacher L, Cartwright T et al. (2005) Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91: 173–180

    Article  PubMed  CAS  Google Scholar 

  64. Scott IU, Flynn HW (2007) Reducing the risk of endophthalmitis following intravitreal injections. Retina 27: 10–12

    Article  PubMed  Google Scholar 

  65. Shah MA, Ilson D, Kelsen DP (2005) Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol 23: 2574–2576

    Article  PubMed  Google Scholar 

  66. Tan CS, Sanjay S, Eong KG (2007) Charles Bonnet syndrome (visual hallucinations) after intravitreal avastin injection for age-related macular degeneration. Am J Ophthalmol 144: 330

    Article  PubMed  Google Scholar 

  67. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H et al. (2008) Twelve-month safety of intravitreal injections of bevacizumab (Avastin(R)): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246: 81–87

    Article  PubMed  CAS  Google Scholar 

  68. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, D’Amico DJ, Masonson HN, Patel M et al. (2006) Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 113: 992–1001

    Article  Google Scholar 

  69. Ziemssen F, Bartz-Schmidt KU, Grisanti S (2006) (Neben-)Wirkungen der VEGF Inhibition. Ophthalmologe103: 484–492

  70. Ziemssen F, Luke M, Messias A et al (2007) Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. Int Ophthalmol (Jul)

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehungen hin: Heinrich Heimann hält auf Honorarbasis Vorträge für Novartis Pharma Schweiz AG, Nürnberg, und Pfizer GmbH, Karlsruhe. Carsten H. Meyer wurde von Novartis Pharma Schweiz AG, Nürnberg, und Pfizer GmbH, Karlsruhe, für Vorträge und die Teilnahme an Advisory Boards finanziell unterstützt. Die Augenklinik der Universität Bonn nimmt an diversen wissenschaftlichen Studien zu VEGF-Inhibitoren teil. Focke Ziemssen übernahm für Novartis Pharma Schweiz AG, Nürnberg, honorierte Vortragstätigkeiten. Die Universitäts-Augenklinik in Tübingen nimmt an zahlreichen klinischen Studien mit VEGF-Inhibitoren teil.

Author information

Authors and Affiliations

  1. Augenklinik, Universitätsklinikum Bonn, Ernst-Abbe-Straße 2, 53127, Bonn, Deutschland

    C.H. Meyer

  2. Augenklinik, Universität Tübingen, Tübingen, Deutschland

    F. Ziemssen

  3. St. Paul’s Eye Unit, Royal Liverpool University Hospital, Liverpool, Großbritannien

    H. Heimann

Authors
  1. C.H. Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Ziemssen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Heimann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C.H. Meyer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meyer, C., Ziemssen, F. & Heimann, H. Intravitreale Injektion. Ophthalmologe 105, 143–157 (2008). https://doi.org/10.1007/s00347-008-1701-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00347-008-1701-7

Schlüsselwörter

Keywords

Search

Navigation